chevron_leftBack
As of 13 June 2026, BioVie Inc. has a market cap of $11.99M USD, ranking #40289 globally and #5246 in the United States.
It ranks #3593 in the Healthcare sector, and #701 in the Biotechnology industry.
Key Stats
Market Cap
$11.99MUSD
Enterprise Value
-$8.34MUSD
EBITDA (TTM)
-$17.97MUSD
Net Income (TTM)
-$17.48MUSD
PB Ratio
0.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Cuong Viet Do
open_in_new
Employees
13
Founded
2013
Website
bioviepharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.6% | -1.8% | 16% | 28% | -15% | -81% |
News
Loading...
BIVI Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BIVI
BioVie Inc Ordinary Shares - Class A
ISIN: US09074F5044
Shares Out.:
Shares Outstanding:
7.542M1
Shares Float:
7.184M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.59 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About BioVie Inc.
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
2M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
1M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
230K%
|
-
|
|
NYSE: IQV
|
$26.3B
219K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
209K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
151K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
399K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
374K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
353K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
353K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
234K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
214K%
|
-
|
chevron_leftBack